Factor | Susceptible to cefepime (n=159) | Not susceptible to cefepime (n=40) | p-value |
---|---|---|---|
Age (years) | 38 (20-51) | 17 (2-51) | 0.013 |
Gender (male) | 89 (56.0) | 19 (47.5) | 0.456 |
Underlying disease | Â | Â | 0.320 |
 Acute myeloid leukemia | 117 (73.6) | 28 (70.0) |  |
 Acute lymphoblastic leukemia | 26 (16.4) | 9 (22.5) |  |
 Other leukemias | 6 (3.1) | 1 (2.5) |  |
 Non-Hodgkin lymphoma | 8 (5.0) | 1 (2.5) |  |
 Multiple myeloma | 2 (1.3) | 1 (2.5) |  |
Complete remission status | 104 (65.4) | 19 (47.5) | 0.037 |
Preceding therapy | Â | Â | 0.732 |
 Conventional chemotherapy | 151 (95.0) | 38 (95.0) |  |
 Hematopoietic cell transplantation |  |  |  |
  Autologous | 6 (3.8) | 2 (5.0) |  |
  Allogeneic | 2 (1.3) | 0 (0.0) |  |
Duration after the preceding therapy (days) | 12 (10-14) | 13 (10-13) | 0.568 |
Antibacterial prophylaxis* | Â | Â | <0.001 |
 None | 4 (2.5) | 1 (2.7) |  |
 Trimethoprim/sulfamethoxazole | 31 (19.5) | 20 (54.1) |  |
 Ciprofloxacin | 124 (78.0) | 16 (43.2) |  |
Probability of antibacterial therapy after chemotherapy†(%) | 84.0 ± 29.6 | 81.8 ± 32.0 | 0.864 |
Previous antibacterial therapy for febrile neutropenia†(times) | 1 (1-2) | 2 (1-2) | 0.284 |
Accompanying symptoms | Â | Â | Â |
 Oral mucositis | 35 (22.0) | 6 (15.0) | 0.327 |
 Cough | 18 (11.3) | 2 (5.0) | 0.377 |
 Sputum | 6 (3.8) | 3 (7.5) | 0.388 |
 Rhinorrhea | 1 (0.6) | 0 (0.0) | 1.000 |
 Diarrhea | 50 (31.4) | 8 (20.0) | 0.154 |
 Abdominal pain | 34 (21.4) | 4 (10.0) | 0.102 |
Polymicrobial infection | Â | Â | Â |
  Other bacterial infection | 17 (10.7) | 5 (12.5) | 0.779 |
  Fungal infection | 16 (10.1) | 2 (5.0) | 0.537 |
Complications attributable to VSB | 23 (14.5) | 3 (7.5) | 0.243 |
 Ventilator care | 8 (5.0) | 0 (0.0) | 0.362 |
 Acute respiratory distress syndrome | 6 (3.8) | 0 (0.0) | 0.602 |
 Shock | 23 (14.5) | 3 (7.5) | 0.243 |
 Death | 4 (2.5) | 0 (0.0) | 0.585 |
Overall death | 13 (8.2) | 1 (2.5) | 0.309 |
Laboratory findings | Â | Â | Â |
 White blood cell count (/μL) | 60 (20-160) | 40 (20-118) | 0.194 |
 Absolute neutrophil count (/μL) | 0 (0-0) | 0 (0-0) | 0.915 |
 Duration of neutropenia before the diagnosis of VSB (days) | 5 (4-7) | 7 (5-11) | 0.021 |
 Total duration of neutropenia (days) | 16 (12-23) | 20 (12-24) | 0.094 |
 Peak C-reactive protein level (mg/dL) | 19.6 (13.1-26.1) | 17.1 (9.3-28.1) | 0.397 |